Medicare database analysis presented at the 2022 American Urology Association Meeting found 44% lower total costs and 77% lower clinically-advanced costs with Guidance UTI versus standard urine culture (SUC)
IRVINE, Calif., May 14, 2022 /PRNewswire/ — Real-world evidence from a Medicare database analysis presented today at the 2022 American Urology Association (AUA) Meeting shows that Guidance UTI testing is associated with reductions in critical adverse outcomes, healthcare resource utilization and costs for complicated urinary tract infections (cUTIs) compared to standard urine culture (SUC). The comparative analysis was designed to examine outcomes of one year of cUTI treatment guided by either Guidance UTI or SUC.
cUTIs are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes. Annually, UTIs contribute to 10.5 million office visits and carry a cost of approximately $3.5 billion in the U.S.i Guidance UTI is an advanced rapid result test that combines PCR and Pooled Antibiotic Susceptibility Testing (P-AST™), which better address polymicrobial infections where bacterial interactions can impact antibiotic resistance.
“We conducted this analysis because evidence-based testing is of critical importance to diagnostic laboratories in order to improve the quality of patient care and ensure better use of healthcare resources,” said Mohit Mathur, SVP of Medical Affairs at Pathnostics. “Our commitment to providing real-world evidence is a key part of our vision to create a new standard of care in UTI testing and our overall mission to pioneer a better future by providing innovative solutions to address diagnostic and therapeutic dilemmas. The findings reinforce the real-world benefits of Guidance UTI’s increased sensitivity, reduced time to results, and P-AST results to patients, providers, and the healthcare system.”
Analysis Methodology and Highlights: